ArticleBMC public health2026
Association of serum 25-hydroxyvitamin D concentrations with premature mortality in adult U.S. patients with sarcopenia.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLower serum 25-hydroxyvitamin D ([25(OH)D]) levels may be associated with a higher risk of premature mortality in patients with sarcopenia; however, this relationship remains inadequately characterized in U.S. POPULATIONS:
methodsData were from 9,561 participants in NHANES 2011-2018. Sarcopenia was defined using FNIH criteria (appendicular lean mass/BMI). Weighted multivariable logistic regression was used to examine the association between serum 25(OH)D levels and sarcopenia prevalence. Among participants with sarcopenia, premature mortality (death before age 75) was assessed by linking data to the National Death Index; weighted Cox proportional hazards models estimated hazard ratios (HRs) for the association between 25(OH)D levels and premature mortality risk. The proportional hazards assumption was verified using Schoenfeld residuals, with a Weibull parametric model applied as a sensitivity analysis. Dose-response relationships were evaluated using restricted cubic splines, and subgroup analyses with interaction tests were performed to explore differences across key subgroups.
resultsAfter multivariable adjustment (adjusting for demographics, lifestyle factors, comorbidities, and laboratory biomarkers), serum 25(OH)D levels were inversely associated with the prevalence of sarcopenia (OR = 0.989 per 1 nmol/L increase; 95% CI: 0.983-0.995; P < 0.001), with this inverse association being more pronounced in males. Among the 828 participants with sarcopenia, 17 premature deaths were documented (2.1%). Higher serum 25(OH)D levels suggested a trend toward reduced premature mortality risk (HR = 0.964, 95% CI: 0.928-1.001, P = 0.051), which was further supported by sensitivity analysis (P = 0.028). No significant interactions were observed for mortality, although analyses were limited by low statistical power.
conclusionsSerum 25(OH)D levels were independently and inversely associated with sarcopenia prevalence, with each 1 nmol/L increase reducing risk by 1.07% (OR = 0.989), particularly in males. Higher 25(OH)D levels also trended toward reduced premature mortality in sarcopenic patients (HR = 0.964, P = 0.051; sensitivity analysis P = 0.028). Thus, monitoring serum 25(OH)D may have potential value in sarcopenia management, though further validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.